CAPLIPOINT · Healthcare
Caplin Point Laboratories Ltd. reported revenue of ₹493 cr for October to December 2024, +13.1% on the year and +2.1% on the quarter. It is the highest quarterly revenue in the last 7 quarters on record.
Operating profit (EBITDA) was ₹162 cr, a margin of 32.9%, +29 bps on the year and −130 bps on the quarter. Over the last 7 quarters the margin has ranged from 32.0% to 34.2%, averaging 32.9%. Operating costs grew +12.6%, broadly with revenue, so operating profit kept pace with sales.
Net profit was ₹140 cr, +16.7% on the year and +6.9% on the quarter, with earnings per share of ₹18.28. Profit before other income, one-offs and tax grew 14.1%, so the profit growth came from the business itself. The tax rate of 21% is in line with its recent average.
On earnings per share of ₹67.81 over the last four quarters, the stock at ₹2,298.40 trades at 33.9 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Exceptional items that recur, Finance cost rising, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹410 cr | ₹436 cr | ₹453 cr | ₹459 cr | ₹483 cr | ₹493 cr | ₹502 cr | ₹510 cr | ₹534 cr | ₹543 cr | ₹600 cr | ₹610 cr |
| YoY | — | — | — | +16% | +18% | +13% | +11% | +11% | +11% | +10% | +20% | +20% |
| EBITDA margin | 33.4% | 32.6% | 32.0% | 33.1% | 34.2% | 32.9% | 33.5% | 34.9% | 35.4% | 35.0% | 34.0% | 34.9% |
| Other income, % of PBT | 14% | 12% | 12% | 12% | 13% | 18% | 15% | 13% | 15% | 17% | 13% | 15% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% |
| Net profit | ₹116 cr | ₹120 cr | ₹121 cr | ₹125 cr | ₹131 cr | ₹140 cr | ₹145 cr | ₹151 cr | ₹160 cr | ₹166 cr | ₹173 cr | ₹179 cr |
| YoY | — | — | — | +20% | +13% | +17% | +20% | +21% | +22% | +19% | +19% | +19% |
| Core profit YoY | — | — | — | +17% | +18% | +14% | +17% | +19% | +16% | +16% | +23% | +19% |
| EPS | ₹15.13 | ₹15.43 | ₹16.01 | ₹16.31 | ₹17.21 | ₹18.28 | ₹18.76 | ₹20.10 | ₹20.32 | ₹21.56 | ₹22.38 | ₹23.27 |
| Flags | · | · | · | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Caplin Point Laboratories Ltd. reported revenue of ₹493 cr (+13.1% on the year) and net profit of ₹140 cr (+16.7% on the year) for October to December 2024.
Profit before other income, exceptional items and tax moved +14.1% on the year, against +16.7% for reported profit.
None of the 6 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.